Chapter 1 Newborn Screening for Intellectual Disability. Past, Present, and Future

International Review of Research in Mental Retardation

Volumn 36, Issue , 2008, Pages 1-25

  Bailey, Don ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58249084042     PISSN: 00747750     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7750(08)00001-3     Document Type: Review

References (75)

1. Acharya K., Ackerman P.D., and Ross L.F. Pediatricians' attitudes toward expanding newborn screening. Pediatrics 116 (2005) e476-e484
2. Alexander D., and Hanson J.W. NICHD research initiative in newborn screening. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 301-304
3. American Academy of Pediatrics Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics 107 (2001) 1451-1455
4. American Academy of Pediatrics Newborn Screening Task Force. Serving the family from birth to the medical home. Newborn screening: A blueprint for the future. Pediatrics 106 Supplement (2000) 389-427
5. American Society of Human Genetics/American College of Medical Genetics (ASHG/ACMG). Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Journal of Human Genetics 57 (1995) 1233-1241
6. In: Andrews L.B., Fullarton J.E., Holtzman M.A., and Motulsky A.G. (Eds). Assessing genetic risks: Implications for health and social policy (1994), National Institute of Sciences, Washington, DC
7. Anido A., Carlson L.M., Taft L., and Sherman S.L. Women's attitudes toward testing for fragile X carrier status: A qualitative analysis. Journal of Genetic Counseling 14 (2005) 295-301
8. Anido A., Carlson M., and Sherman S.L. Attitudes toward fragile X mutation carrier testing from women identified in a general population survey. Journal of Genetic Counseling 16 (2007) 97-104
9. Bailey D.B. The federal role in early intervention: Prospects for the future. Topics in Early Childhood Special Education 20 2 (2000) 71-78
10. Bailey D.B. Newborn screening for fragile X syndrome. Mental Retardation and Developmental Disabilities Research Reviews 10 (2004) 3-10
11. Bailey D.B., Armstrong F.D., Kemper A.R., Skinner D., and Warren S.F. Supporting family adaptation to pre-symptomatic and "untreatable" conditions in an era of expanded newborn screening. Journal of Pediatric Psychology 33 (2008) 1-14
12. Bailey D.B., Aytch L.S., Odom S.L., Symons F., and Wolery M. Early intervention as we know it. Mental Retardation and Developmental Disabilities Research Reviews 5 (1999) 11-20
13. Bailey D.B., Beskow L.M., Davis A.M., and Skinner D. Changing perspectives on the benefits of newborn screening. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 27-279
14. Bailey D.B., Bruder M.B., Hebbeler K., Carta J., DeFosset M., Greenwood C., et al. Recommended outcomes for families of young children with disabilities. Journal of Early Intervention 28 (2006) 227-251
15. Bailey D.B., and Gariepy J. Critical periods. In: Haith M.M., and Benson J.B. (Eds). Encyclopedia of infant and early childhood development (2008), Elsevier, San Diego, CA 322-332
16. Bailey D.B., Hebbeler K., Scarborough A., Spiker D., and Mallik S. First experiences with early intervention: A national perspective. Pediatrics 113 (2004) 887-896
17. Bailey D.B., Hebbeler K., Spiker D., Scarborough A., Mallik S., and Nelson L. 36-month outcomes for families of children with disabilities participating in early intervention. Pediatrics 116 (2005) 1346-1352
18. Bailey D.B., Nelson L., Hebbeler K., and Spiker D. Modeling the impact of formal and informal supports for young children with disabilities and their families. Pediatrics 120 (2007) e992-e1001
19. Bailey D.B., Roberts J.E., Mirrett P., and Hatton D. Identifying infants and toddlers with fragile X syndrome: Issues and recommendations. Infants and Young Children 14 (2001) 24-33
20. Bailey D.B., Skinner D., Davis A., Whitmarsh I., and Powell C. Ethical, legal, and social concerns about expanded newborn screening: Fragile X syndrome as a prototype for emerging issues. Pediatrics 121 (2008) e693-e704
21. Bailey D.B., Skinner D., Hatton D., and Roberts J. Family experiences and factors associated with the diagnosis of fragile X syndrome. Developmental and Behavioral Pediatrics 21 (2000) 315-321
22. Bailey D.B., Skinner D., and Sparkman K. Discovering fragile X syndrome: Family experiences and perceptions. Pediatrics 111 (2003) 407-416
23. Bailey D.B., Skinner D., and Warren S.F. Newborn screening for developmental disability: Reframing presumptive benefit. American Journal of Public Health 95 (2005) 1889-1893
24. Baranek G.T., Danko C.D., Skinner M.L., Bailey D.B., Hatton D.D., Roberts J.E., et al. Video analysis of sensory-motor features in infants with fragile X syndrome at 9-12 months of age. Journal of Autism and Developmental Disorders 35 (2005) 645-656
25. Berry H.K., O'Grady D.J., Perlmutter L.J., and Bofinger M.K. Intellectual development and academic achievement of children treated early for phenylketonuria. Developmental Medicine and Child Neurology 21 (1979) 311-320
26. Bodamer O.A., Hoffman G.F., and Lindner M. Expanded newborn screening in Europe 2007. Journal of Inherited Metabolic Disorders 30 (2007) 439-444
27. Borrajo G.J.C. Newborn screening in Latin America at the beginning of the 21st century. Journal of Inherited Metabolic Disorders 30 (2007) 466-481
28. Botkin J.R. Research for newborn screening: Developing a national framework. Pediatrics 116 (2005) 862-871
29. Botkin J.R., Clayton E.W., Fost N.C., Burke W., Murray T.H., Baily M.A., et al. Newborn screening technology: Proceed with caution. Pediatrics 117 (2006) 1793-1799
30. Comeau A.M., Parad R.B., Dorkin H.L., Dovey M., Gerstle R., Haver K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: A cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004) 1573-1581
31. Committee for the Study of Inborn Errors of Metabolism. Genetic screening programs, principles, and research (1975), National Academy of Sciences, Washington, DC
32. Cook E.H. Genetics of autism. Mental Retardation and Developmental Disabilities Research Reviews 4 (1998) 113-120
33. DeFries J.C., and Alarcon M. Genetics of specific reading disability. Mental Retardation and Developmental Disabilities Research Reviews 2 (1996) 39-47
34. Dhondt J.-L. Neonatal screening: From the 'Guthrie age' to the 'genetic age. Journal of Inherited Metabolic Disorders 30 (2007) 418-422
35. Engle P.L., Black M.M., Behrman J.R., de Mello M.C., Gertler P.J., Kapiriri L., et al. Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. Lancet 369 (2007) 229-242
36. Fenning R.M., Baker J.K., Baker B.L., and Crnic K.A. Parenting children with borderline intellectual functioning: A unique risk population. American Journal on Mental Retardation 112 (2007) 107-121
37. Grob R. Parenting in the genomic age: The 'cursed blessing' of newborn screening. New Genetics and Society 25 (2006) 159-170
38. Grody W.W. Ethical issues raised by genetic testing with oligonucleotide mocroarrays. Molecular Biotechnology 23 (2003) 127-138
39. Grosse S.D. Does newborn screening save money? The difference between cost-effective and cost-saving interventions. Journal of Pediatrics 146 (2005) 168-170
40. Grosse S.D., Boyle C.A., Kenneson A., Khoury M.J., and Wilfond B.S. From public health emergency to public health services: The implications of evolving criteria for newborn screening panels. Pediatrics 117 (2006) 923-929
41. Guralnick M. Early intervention for children with intellectual disabilities: Current knowledge and future prospects. Journal of Applied Research in Intellectual Disabilities 18 (2005) 313-324
42. Gurian E.A., Kinnamon D.D., Henry J.J., and Waisbren S.E. Expanded newborn screening for biochemical disorders: The effect of a false-positive result. Pediatrics 117 (2006) 1915-1921
43. Hacia J.G., and Collins F.S. Mutational analysis using oligonucleotide microarrays. Journal of Medical Genetics 36 (1999) 730-736
44. Han X., Powell B.R., Phalin J.L., and Chehab F.F. Mosaicism for a full mutation, premutation, and deletion of the CGG repeats results in 22% FMRP and elevated FMR1 mRNA levels in a high-functioning fragile X male. American Journal of Medical Genetics 140A (2006) 1463-1471
45. Hewlett J., and Waisbren S.E. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. Journal of Inherited Metabolic Disease 20 (2006) 677-682
46. Hiraki S., Ormond K.E., Kim K., and Ross L.F. Attitudes of genetic counselors toward expanding newborn screening and offering predictive genetic testing to children. American Journal of Medical Genetics Part A 140A (2006) 2312-2319
47. Holtzman N.A., and Watson M.S. Promoting safe and effective genetic testing in the United States: Final report of the Task Force on Genetic Testing (1997), National Institutes of Health, Bethesda, MD
48. Howell R.R. Introduction: Newborn screening. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 229
49. Howell R.R. The high price of false positives. Molecular Genetics and Metabolism 87 (2006) 180-183
50. Howse J.L., Weiss M., and Green N.S. Critical role of the March of Dimes in the expansion of newborn screening. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 280-287
51. Inlow J.K., and Restifo L.L. Molecular and comparative genetics of mental retardation. Genetics 166 (2004) 835-881
52. Khoury M.J., Gwinn M., Burke W., Bowen S., and Zimmern R. Will genomics widen or help heal the schism between medicine and public health. American Journal of Preventive Medicine 33 (2007) 310-317
53. Khoury M.J., Jones K., and Grosse S.D. Quantifying the health benefits of genetic tests: The importance of a population perspective. Genetics in Medicine 8 (2006) 191-195
54. Koch R., and de la Cruz F. Historical aspects and overview of research on phenylketonuria. Mental Retardation and Developmental Disabilities Research Reviews 5 (1999) 101-104
55. Materin D., and Rinaldo P. Newborn screening: Opportunities and challenges of tandem mass spectrometry. Clinical Laboratory News (2003, August) 12-15
56. McGuire A.L., Cho M.K., McGuire S.E., and Caulfield T. The future of personal genomics. Science 317 (2007) 1687
57. Mirrett P.L., Bailey D.B., Roberts J.E., and Hatton D.D. Developmental screening and detection of developmental delays in infants and toddlers with fragile X syndrome. Developmental and Behavioral Pediatrics 25 (2004) 21-27
58. Padilla C.D., and Therrell B.L. Newborn screening in the Asia Pacific region. Journal of Inherited Metabolic Disorders 30 (2007) 490-506
59. Plomin R., and McGuffin P. Psychopathology in the postgenomic era. Annual Review of Psychology 54 (2003) 205-228
60. Pollit R.J. Introducing new screens: Why are we all doing different things. Journal of Inherited Metabolic Disorders 30 (2007) 423-429
61. Ramey S.L., and Ramey C.T. Early experience and early intervention for children "at risk" for developmental delay and mental retardation. Mental Retardation and Developmental Disabilities Research Reviews 5 (1999) 1-10
62. Roberts J.E., Hatton D.D., and Bailey D.B. Development and behavior of male toddlers with fragile X syndrome. Journal of Early Intervention 24 (2001) 207-223
63. Rolland J.S., and Williams J.K. Toward a biopsychosocial model for 21st-century genetics. Family Process 44 (2005) 3-24
64. Saadallah A.A., and Rashed M.S. Newborn screening: Experiences in the Middle East and North Africa. Journal of Inherited Metabolic Disorders 30 (2007) 482-489
65. Sices L., Feudtner C., McLaughlin J., Drotar D., and Williams M. How do primary care physicians identify young children with developmental delays? A national survey. Developmental and Behavioral Pediatrics 24 (2003) 409-417
66. Skinner D., Sparkman K., and Bailey D.B. Screening for fragile X syndrome: Parent attitudes and perspectives. Genetics in Medicine 5 (2003) 378-384
67. Tarini B.A., Christakis D.A., and Welch H.G. State newborn screening in the tandem mass spectrometry era: More tests, more false-positive results. Pediatrics 118 (2006) 448-456
68. Therrell B.L., and Adams J. Newborn screening in North America. Journal of Inherited Metabolic Disorders 30 (2007) 447-465
69. Therrell B.L., and Hannon W.H. National evaluation of U.S. newborn screening system components. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 236-245
70. Tunis S.R., Stryer D.B., and Clancy C.M. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association 290 (2003) 1624-1632
71. United States General Accounting Office. Newborn screening: Characteristics of state programs (2003), U.S. General Accounting Office, Washington, DC (Report GAO-03-449)
72. Walker S.P., Wachs T.D., Gardner J.M., Lozoff B., Wasserman G.A., Pollitt E., et al. Child development: Risk factors for adverse outcomes in developing countries. Lancet 369 (2007) 145-157
73. Watson M.S. Current status of newborn screening: Decision-making about the conditions to include in screening programs. Mental Retardation and Developmental Disabilities Research Reviews 12 (2006) 230-235
74. In: Watson M.S., Mann M.M., Lloyd-Puryear M.A., Rinaldo P., and Howell R.R. (Eds). Newborn screening: Toward a uniform screening panel and system. Genetics in Medicine 8 Supplement 1 (2006) 1S-252S
75. Wilson J.M.G., and Junger F. Principles and practice of screening for disease. Public Health Papers No. 34 (1968), World Health Organization, Geneva